N/A
Completed N=49
Transcranial Magnetic Stimulation for the Treatment of Veterans With Alcohol Use Disorders
Source: ClinicalTrials.gov NCT03191266 ↗Enrolled (actual)
49
Serious AEs
2.3%
Results posted
Jan 2026
Primary outcomePrimary: Number of Participants Who Abstained From Alcohol — 13; 9 Participants — p=0.05
Summary
At least 60% of Veterans with an alcohol use disorder will relapse within 6 months of treatment, irrespective of the type of treatment they receive. This indicates that currently available interventions for treating AUD in Veterans are not effective in helping them achieve long-term sobriety. Repetitive transcranial magnetic stimulation (rTMS) is a brain stimulation method that is at the forefront of innovative, non-invasive, and safe treatments for AUD. However, there have been no studies that specifically determined the effectiveness of rTMS treatment for Veterans with AUD. This project will evaluate the effectiveness of rTMS treatment in promoting long-term abstinence in Veterans suffering from AUD. Assisting Veterans in achieving long-term and sustained sobriety is critical because it is associated with the best medical, cognitive, psychiatric, and psychosocial recovery from AUD.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Abstained From Alcohol |
13; 9 | 0.05 |
| SECONDARY Glutamate Concentration in the Left Dorsolateral Prefrontal Cortex (as Measured With Single Voxel Spectroscopy) |
26.2; 19.7 | 0.11 |
| SECONDARY Volume in Anterior Frontal Cortical Regions (as Measured With FreeSurfer) |
6587; 6236; 14778; 14071; 23503; 21086 | 0.92 |
| SECONDARY BDNF Polymorphisms (as Measured With TaqMan Genotyping Assays or Similar Assays) |
5; 4 | 0.24 |
Eligibility Criteria
Inclusion Criteria
- The study will be open to male and females, regardless of race and ethnic origin, who are in active treatment for an alcohol use disorder (AUD).
- Meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria for AUD, and alcohol is self-identified as primary substance of misuse.
- Actively in treatment at VA Palo Alto HCS Addiction Treatment Service, and able to read, verbalize understanding, and voluntarily sign the Informed Consent Form prior to participation in study procedures.
- Participants will be accepted if taking medications specifically for the treatment of MDD, cigarette smoking, or for other psychiatric conditions.
- as long as the medications are not documented to lower seizure threshold
- must be stable on any psychotropic medication for at least 1 month prior to enrollment
- it would be clinically contraindicated to require participants to discontinue such medications for research.
- Participants will be abstinent from alcohol and non-prescribed substances for at least 7 consecutive days prior to active or sham rTMS and no participant demonstrates active acute withdrawal symptoms.
Exclusion Criteria
Psychiatric:
- History of Schizophrenia Spectrum Disorders
- Bipolar Disorders
- A current substance use disorder that exceeds the severity of the AUD
- based on DSM-5 diagnostic criteria
- Current use of an FDA approved medication for treatment of AUD, i.e.:
- disulfiram
- acamprosate
- naltrexone
- Active current suicidal intent or plan
- patients with a previous clinical flag for risk for suicide will be required to have an established safety plan involving their primary psychiatrist and the treatment team before entering the clinical trial
- Any form of previous rTMS or electroconvulsive treatment
Biomedical:
- Including but not limited to uncontrolled thyroid disease
- Unstable congestive heart failure
- Angina
- Other severe cardiac illness as defined by treatment regimen changes in the prior 3 months
- Cerebrovascular accident
- Cancer if 30 minutes
- Any primary or traumatically induced seizure disorder
General:
- Lack of fluency in English
- Wechsler Adult Reading Test below the 7th percentile, i.e.:
- moderate or greater impairment in estimated general intelligence
- Females who are pregnant or actively attempting pregnancy
- conservative exclusion for magnetic resonance research
- Current use of any medication or substance that is documented to lower seizure threshold or has been identified as a contraindication for rTMS treatment
Data sourced from ClinicalTrials.gov (NCT03191266). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.